Drug Combination of Ciprofloxacin and Polymyxin B for the Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Infections: A Drug Pair Limiting the Development of Resistance

Polymyxins are considered as last-resort antibiotics to treat infections caused by <i>Acinetobacter baumannii</i>. However, there are increasing reports of resistance in <i>A. baumannii</i> to polymyxins. In this study, inhalable combinational dry powders consisting of ciprof...

Full description

Saved in:
Bibliographic Details
Main Authors: Junwei Wang (Author), Marc Stegger (Author), Arshnee Moodley (Author), Mingshi Yang (Author)
Format: Book
Published: MDPI AG, 2023-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_92a11d16c99b47e0b8f186c43335fea7
042 |a dc 
100 1 0 |a Junwei Wang  |e author 
700 1 0 |a Marc Stegger  |e author 
700 1 0 |a Arshnee Moodley  |e author 
700 1 0 |a Mingshi Yang  |e author 
245 0 0 |a Drug Combination of Ciprofloxacin and Polymyxin B for the Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Infections: A Drug Pair Limiting the Development of Resistance 
260 |b MDPI AG,   |c 2023-02-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics15030720 
500 |a 1999-4923 
520 |a Polymyxins are considered as last-resort antibiotics to treat infections caused by <i>Acinetobacter baumannii</i>. However, there are increasing reports of resistance in <i>A. baumannii</i> to polymyxins. In this study, inhalable combinational dry powders consisting of ciprofloxacin (CIP) and polymyxin B (PMB) were prepared by spray-drying. The obtained powders were characterized with respect to the particle properties, solid state, in vitro dissolution and in vitro aerosol performance. The antibacterial effect of the combination dry powders against multidrug-resistant <i>A. baumannii</i> was assessed in a time-kill study. Mutants from the time-kill study were further investigated by population analysis profiling, minimum inhibitory concentration testing, and genomic comparisons. Inhalable dry powders consisting of CIP, PMB and their combination showed a fine particle fraction above 30%, an index of robust aerosol performance of inhaled dry powder formulations in the literature. The combination of CIP and PMB exhibited a synergistic antibacterial effect against <i>A. baumannii</i> and suppressed the development of CIP and PMB resistance. Genome analyses revealed only a few genetic differences of 3-6 SNPs between mutants and the progenitor isolate. This study suggests that inhalable spray-dried powders composed of the combination of CIP and PMB is promising for the treatment of respiratory infections caused by <i>A. baumannii</i>, and this combination can enhance the killing efficiency and suppress the development of drug resistance. 
546 |a EN 
690 |a drug combination 
690 |a inhalable dry powders 
690 |a resistance development 
690 |a synergistic effect 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 15, Iss 3, p 720 (2023) 
787 0 |n https://www.mdpi.com/1999-4923/15/3/720 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/92a11d16c99b47e0b8f186c43335fea7  |z Connect to this object online.